Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | ADX-914 | Moderate-to-severe atopic dermatitis (AD) | Phase 2 | Intravenous | Immunology | |
| Amgen Inc. | Tezepelumab - (NAVIGATOR) | Asthma and comorbid nasal polyps | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Amgen Inc. | OTEZLA | Palmoplantar pustulosis for Japanese patients | Phase 2 | oral | Immunology | |
| Amgen Inc. | Avacopan (CCX168) | Hidradenitis Suppurativa (HS) | Phase 2b | Oral | Immunology | |
| Amgen Inc. | Otezla (apremilast) - (DISCREET) | Moderate to severe genital psoriasis | Phase 3 | oral | #N/A | |
| Amgen Inc. | Daxdilimab (HZN-7734) | Alopecia areata | Phase 2 | Intravenous | Immunology | |
| Amgen Inc. | TEPEZZA (Teprotumumab) | Thyroid Eye Disease (TED) - chronic | Phase 3 | Intravenous | Opthalmic | |
| Amgen Inc. | AMG 133 (maridebart cafraglutide) - (MariTide) | Obesity and without diabetes | Phase 2 | Data Released | subcutaneous | Endocrinology |
